B of A Securities Maintains Buy on Intra-Cellular Therapies, Raises Price Target to $91
Portfolio Pulse from Benzinga Newsdesk
B of A Securities analyst Jason Gerberry maintains a Buy rating on Intra-Cellular Therapies (NASDAQ:ITCI) and raises the price target from $82 to $91.
April 17, 2024 | 11:59 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
B of A Securities raises price target for Intra-Cellular Therapies from $82 to $91, maintaining a Buy rating.
The increase in price target by a reputable analyst like Jason Gerberry at B of A Securities suggests a strong confidence in Intra-Cellular Therapies' future performance. This endorsement is likely to positively influence investor sentiment and potentially drive up the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100